Submission Details

RAL-THA-f8a0f917
Molecule(s):
O=C(Nc1nncn1C1CC1)C1CCOc2ccc(Cl)c(Cl)c21

RAL-THA-f8a0f917-1

O=C(Nc1nncn1C1CC1)C1CCOc2ccc(Cl)c(Cl)c21

3-aminopyridine-like Check Availability on Manifold View
Cc1c(Cl)ccc2c1C(C(=O)Nc1nncn1C1CC1)CCO2

RAL-THA-f8a0f917-2

Cc1c(Cl)ccc2c1C(C(=O)Nc1nncn1C1CC1)CCO2

3-aminopyridine-like Check Availability on Manifold View
C[C@H]1C[C@H](C(=O)Nc2nncn2C2CC2)c2cc(Cl)ccc2O1

RAL-THA-f8a0f917-3

C[C@H]1C[C@H](C(=O)Nc2nncn2C2CC2)c2cc(Cl)ccc2O1

3-aminopyridine-like Check Availability on Manifold View
Design Rationale:

Expansion of an early lead JAG-UCB-a3ef7265-20. Add substituents with the further potential to enforce an axial orientation of the carboxamide side chain.

Inspired By:
Discussion:

Contributor: Ralph Robinson, Thames Pharma Partners - Fri, 26 Jun 2020 14:17:21 +0000